SCHEDULE 13G/A 0001777813 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/31/2024 0001736297 Astera Labs, Inc. 04626A103 2901 TASMAN DR. SUITE 205 SANTA CLARA CA 95054 Rule 13d-1(b) Atreides Management, LP b DE 0.00 1836650.00 0.00 1836650.00 1836650.00 1.2 IA PN Atreides Management, LLC b DE 0.00 1836650.00 0.00 1836650.00 1836650.00 1.2 HC Gavin Baker b X1 0.00 1836650.00 0.00 1836650.00 1836650.00 1.2 HC IN Astera Labs, Inc. 2901 TASMAN DR. SUITE 205, SANTA CLARA, CALIFORNIA, 95054. (i) Atreides Management, LP, a Delaware limited partnership registered with the U.S. Securities and Exchange Commission (the SEC), which serves as the investment manager (the Investment Manager) to certain investment funds and/or accounts (the Funds), with respect to the shares of Common Stock (as defined in Item 2(d) below) held by the Funds; (ii) Atreides Management, LLC, a Delaware limited liability company (the GP), which serves as the general partner to the Investment Manager, with respect to the shares of Common Stock held by the Funds; and (iii) Gavin Baker, a United States citizen, who serves as the managing member to the GP with respect to the shares of Common Stock held by the Funds. The foregoing persons are hereinafter sometimes collectively referred to as the Reporting Persons. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. Atreides Management, LP One International Place, Suite 4410 Boston, MA 02110 See response to Item 2(a). N IA HC 1,836,650 1.2% 0 1,836,650 0 1,836,650 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Atreides Management, LP Laura Malone 02/14/2025 Atreides Management, LLC Laura Malone 02/14/2025 Gavin Baker Gavin Baker 02/14/2025 Joint Filing Agreement, dated November 14, 2024, by and among the Reporting Persons, was previously filed with the SEC on November 14, 2024 as Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with respect to Astera Labs, Inc. and is incorporated herein by reference. The percentages used herein and in the rest of this Schedule 13G are calculated based upon the 158,610,853 shares of Common Stock reported to be outstanding by the Issuer as of October 31, 2024 in its Form 10-Q for the quarterly period ended September 30, 2024 filed with the SEC on November 5, 2024. Each Reporting Person hereby expressly disclaims beneficial ownership in the securities reported in this Schedule 13G expect to the extent of its or his pecuniary interest therein (if any) and membership in a "group" as that term is described in Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended.